Enan­ta culls in­ter­nal NASH work, bet­ting on an out-li­cens­ing strat­e­gy in the dis­as­ter-strewn field

Crack­ing NASH has been the holy grail for years in liv­er drug de­vel­op­ment, but the field has so far proven a waste­land for biotech. One biotech is now of­fload­ing in-house clin­i­cal work for two of its NASH drugs af­ter one post­ed lack­lus­ter re­sults as a so­lo ther­a­py.

Enan­ta Phar­ma­ceu­ti­cals has halt­ed in­ter­nal de­vel­op­ment of its two FXR ag­o­nist NASH drugs, EDP-305 and fol­low-up can­di­date EDP-297, and will piv­ot to an out-li­cens­ing strat­e­gy af­ter ear­ly da­ta turned up lit­tle chance of suc­cess for ei­ther drug as a so­lo agent, the com­pa­ny said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER